Literature DB >> 15505732

[Cystic fibrosis at a Brazilian center of excellence: clinical and laboratory characteristics of 104 patients and their association with genotype and disease severity].

Alfonso E Alvarez1, Antonio F Ribeiro, Gabriel Hessel, Carmen S Bertuzzo, José D Ribeiro.   

Abstract

OBJECTIVE: To identify the clinical, laboratory and radiographic characteristics of the cystic fibrosis patients under care at Universidade Estadual de Campinas (UNICAMP) in the last decade of the twentieth century, and to investigate the association of these characteristics with genotype and severity of the disease as measured by the Shwachman score.
METHODS: Descriptive, retrospective and cross-sectional study of the patients assisted at UNICAMP hospital's Cystic Fibrosis Clinic from July 1990 to July 2000.
RESULTS: One hundred and four patients were studied; 53.8% male; 93.3% Caucasian; 89.4% presented with respiratory symptoms; 59.6% presented with digestive symptoms; 5.8% had meconium ileus; 4.8% had diabetes. The mean age at onset of symptoms was 3 months, and the mean age at diagnosis was 2 years and 4 months. At diagnosis, 69.9 and 56.6% of the patients had weight and height below 10th percentile, respectively; in 10.6%, sweat chloride was < 60 mEq/l. Staphylococcus aureus was found in 80.2%, Pseudomonas aeruginosa in 76%, and Burkholderia cepacia in 5.2%. DeltaF508 homozygosis was observed in 18.75%, whereas 62.50% of the patients were DeltaF508 heterozygous. A moderate/severe Shwachman score was found in 15.7%. Eighteen patients died in that period (17.3%). The mean age at death was 7 years and 8 months; median survival after diagnosis was 18 years and 4 months. Patients who have at least one DeltaF508 mutation have more frequent alterations in fecal fat levels when compared to patients who do not have this mutation (p < 0.05). There were no differences in any parameter between DeltaF508 homozygous and heterozygous patients.
CONCLUSIONS: The clinical and laboratory characteristics of the 104 patients studied were similar to the characteristics described for patients in other countries. Exceptions are the higher age at diagnosis and lower survival. Our results support the recommendation for early diagnosis and the need for more treatment opportunities in the population of cystic fibrosis patients.

Entities:  

Mesh:

Year:  2004        PMID: 15505732

Source DB:  PubMed          Journal:  J Pediatr (Rio J)        ISSN: 0021-7557            Impact factor:   2.197


  11 in total

1.  Burkholderia cepacia complex in cystic fibrosis in a Brazilian reference center.

Authors:  Priscila Dentini; Fernando Augusto Lima Marson; Luciana Cardoso Bonadia; Carmen Sílvia Bertuzzo; Antônio Fernando Ribeiro; Carlos Emílio Levy; José Dirceu Ribeiro
Journal:  Med Microbiol Immunol       Date:  2017-09-30       Impact factor: 3.402

Review 2.  Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases.

Authors:  Adriana Haack; Giselle Gonçalves Aragão; Maria Rita Carvalho Garbi Novaes
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

3.  Cystic Fibrosis: Brazilian ENT Experience.

Authors:  Tania Sih; Ricardo Godinho; Leticia Paiva Franco; Otávio Piltcher
Journal:  Int J Otolaryngol       Date:  2012-05-06

4.  [Factors impacting the growth and nutritional status of cystic fibrosis patients younger than 10 years of age who did not undergo neonatal screening].

Authors:  Taís Daiene Russo Hortencio; Roberto José Negrão Nogueira; Fernando Augusto de Lima Marson; Gabriel Hessel; José Dirceu Ribeiro; Antônio Fernando Ribeiro
Journal:  Rev Paul Pediatr       Date:  2015-02-11

5.  Demographic, clinical, and laboratory parameters of cystic fibrosis during the last two decades: a comparative analysis.

Authors:  Fernando Augusto de Lima Marson; Tais Daiene Russo Hortencio; Katia Cristina Alberto Aguiar; Jose Dirceu Ribeiro
Journal:  BMC Pulm Med       Date:  2015-01-15       Impact factor: 3.317

6.  Medications used in pediatric cystic fibrosis population.

Authors:  Stella Pegoraro Alves; Márcia de Azevedo Frank; Denise Bueno
Journal:  Einstein (Sao Paulo)       Date:  2018-11-08

Review 7.  Ecological Succession of Polymicrobial Communities in the Cystic Fibrosis Airways.

Authors:  Rutvij A Khanolkar; Shawn T Clark; Pauline W Wang; David M Hwang; Yvonne C W Yau; Valerie J Waters; David S Guttman
Journal:  mSystems       Date:  2020-12-01       Impact factor: 6.496

8.  A first-year dornase alfa treatment impact on clinical parameters of patients with cystic fibrosis: the Brazilian cystic fibrosis multicenter study.

Authors:  Tatiana Rozov; Fernando Antônio A E Silva; Maria Angélica Santana; Fabíola Villac Adde; Rita Heloisa Mendes
Journal:  Rev Paul Pediatr       Date:  2013-12

9.  Repeatability and Diagnostic Value of Nasal Potential Difference in a Genetically Admixed Population.

Authors:  Izabela Rocha Sad; Laurinda Yoko Shinzato Higa; Teresinha Leal; Raisa da Silva Martins; Ana Claudia de Almeida; Eloane Goncalves Ramos; Giselda Maria Kalil de Cabello; Maria Virginia Marques Peixoto
Journal:  J Clin Med Res       Date:  2015-12-03

10.  Nasal endoscopic evaluation of children and adolescents with cystic fibrosis.

Authors:  Letícia Paiva Franco; Paulo Augusto Moreira Camargos; Helena Maria Gonçalves Becker; Roberto Eustáquio Santos Guimarães
Journal:  Braz J Otorhinolaryngol       Date:  2009 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.